Business Wire

  1. Overture Life Launches Global ICSI.A Center Of Excellence Program, Bringing The World's First Automated ICSI Into Clinical Use Across Five Leading Global Fertility Centers 6/25/2026

    Overture Life, the global leader in automated IVF and the first company to achieve live births from both robotic fertilization and robotic egg freezing, announced the launch of its ICSI.A Center of Excellence Program, with the first clinical deployments of the world's first automated intracytoplasmic sperm injection (ICSI) workstation at five leading fertility centers: CERAS in Peru, Memorial Hospital in Turkey, CENALFES in Bolivia, Seoul IVF in South Korea, and Procrearte in Argentina.

  2. Verici Dx Receives New York State Approval, Establishing Nationwide Access To Tutivia Kidney Transplant Rejection Test 6/24/2026

    Verici Dx plc, a developer of advanced clinical diagnostics for organ transplant, today announced it has received clinical laboratory accreditation from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP).

  3. StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide 6/24/2026

    StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation.

  4. Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development And AI-Enabled Research At BIO International 2026 6/22/2026

    Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster.

  5. PHC Launches Cell-IQ CO₂ Incubators With Active Humidity Control, Creating Critical Stability For Research Samples 6/18/2026

    PHC Corporation of North America (PHCNA), provider of PHCbi cell culture and sample preservation solutions across North America and Latin America, has introduced a new series of laboratory incubators featuring active hybrid humidification technology and enhanced contamination control.

  6. QIAGEN Expands QIAcuity Gene Expression Portfolio To Accelerate Digital PCR Adoption Across Research And Biopharma 6/15/2026

    QIAGEN N.V. today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications.

  7. Guardant Health Announces FDA Approval Of Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim's HERNEXEOS 6/11/2026

    Guardant Health, Inc., a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic (CDx) for Boehringer Ingelheim’s HERNEXEOS (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option.

  8. Predicta Biosciences And CIMA LAB Diagnostics Announce Agreement To Advance Ultrasensitive Blood-Based Diagnostics For Multiple Myeloma And Other Hematological Malignancies 6/10/2026

    Predicta Biosciences, a company building ultra-sensitive molecular and immune diagnostic platforms, and CIMA LAB Diagnostics from the Clínica Universidad de Navarra, a leading European University Medical Center, today announced a partnership to offer a combined service that integrates CIMA LAB’s flow cytometry capabilities with the GenoPredicta assay.

  9. Personalis Enables Global Biopharma Support With CE-IVD Marked Specimen Collection Kits 6/9/2026

    Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union’s In Vitro Diagnostic Regulation (IVDR).

  10. Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio At ASM Microbe 2026 6/4/2026

    At ASM Microbe 2026, Bruker Corporation’s Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics.